摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-吡啶)-5-(4-吡啶)-1,2,4-三唑 | 36770-50-0

中文名称
3-(2-吡啶)-5-(4-吡啶)-1,2,4-三唑
中文别名
——
英文名称
3-(2'-pyridyl)-5-(4''-pyridyl)-1,2,4-triazole
英文别名
3-(2-pyridyl)-5-(4-pyridyl)-1H-1,2,4-triazole;3-(2-pyridyl)-5-(4-pyridyl)-1,2,4-triazole;2,4'-(1H-[1,2,4]triazole-3,5-diyl)-bis-pyridine;Hdpt24;2-(3-pyridin-4-yl-1H-1,2,4-triazol-5-yl)pyridine
3-(2-吡啶)-5-(4-吡啶)-1,2,4-三唑化学式
CAS
36770-50-0
化学式
C12H9N5
mdl
MFCD00101970
分子量
223.237
InChiKey
WOFXUCJTFGKKIF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    260-261 °C(Solv: ethanol (64-17-5))
  • 沸点:
    515.1±56.0 °C(Predicted)
  • 密度:
    1.303±0.06 g/cm3(Predicted)
  • 溶解度:
    23.1 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.4
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090

SDS

SDS:8d9e26057aa4af49bfb0083ed1baf4a5
查看

反应信息

  • 作为反应物:
    描述:
    3-(2-吡啶)-5-(4-吡啶)-1,2,4-三唑N,N-二甲基甲酰胺 为溶剂, 生成 [Co(3-(2'-pyridyl)-5-(4''-pyridyl)-1,2,4-triazole(-1H))]2*H2O
    参考文献:
    名称:
    DMF/H2O Volume Ratio Controls the Syntheses and Transformations of a Series of Cobalt Complexes Constructed Using a Rigid Angular Multitopic Ligand
    摘要:
    Through middle-temperature solvothermal reactions of CoCl2 center dot 6H(2)O with the rigid-angled ligand 3-(2'-pyridyl)-5(4 ''-pyridyl)-1,2,4-triazole (Hdpt24), we obtained the three cobalt complexes {[Co(dpt24)(2))](3)center dot 4DMF center dot 1.5H(2)O}(n) (1), {[Co(dpt24)(2))](2)center dot H2O}(n) (2), and Co(dpt24)(2)(Hdpt24)center dot H2O] (4) at N,N-dimethylformamide (DMF)/H2O volume ratios of 9:1, 1:1, and 0:1, respectively. Interestingly, 1 underwent transformations into 2, {[Co(dpt24)(2)]center dot 0.5DMF}(n) (3), and 4 when treated with DMF/H2O at volume ratios of 1:1, 1:9, and 0:1, respectively. Moreover, 3 and 4 converted back to 1 in 9:1 DMF/H2O and to 2 in 1:1 DMF/H2O; 3 transformed into 4 in H2O and vice versa in 1:9 DMF/H2O. Structurally, 1 is a three-dimensional (3D) 2-fold interpenetrating distorted NbO-type complex, 2 possesses a two-dimensional layer metal-organic framework, 3 is a 3D 2-fold interpenetrating typical NbO-type complex, and 4 is a wheel-shaped mononuclear neutral complex. This approach, using a mixed solvent's component ratio to direct the syntheses and conversions of four cobalt complexes, provides unprecedented control for crystal engineering.
    DOI:
    10.1021/ic902548f
  • 作为产物:
    参考文献:
    名称:
    Discovery of 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia
    摘要:
    Our previous study identified 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-4-pyridyl)-1H-[1,2,4]-triazol-3-yl]-benzonitrile (2) as a safe and potent xanthine oxidoreductase (XOR) inhibitor for the treatment of hyperuricemia. Here, we synthesized a series of 3,5-dipyridyl-1,2,4-triazole derivatives and, in particular, examined their in vivo activity in lowering the serum uric acid levels in rats. As a result, we identified 3-(3-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole (FYX-051, compound 39) to be one of the most potent XOR inhibitors; it exhibited an extremely potent in vivo activity, weak CYP3A4-inhibitory activity and a better pharmacokinetic pro. le than compound 2. Compound 39 is currently being evaluated in a phase 2 clinical trial. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2009.08.091
点击查看最新优质反应信息

文献信息

  • Synthesis of 5-aryl-3-C-glycosyl- and unsymmetrical 3,5-diaryl-1,2,4-triazoles from alkylidene-amidrazones
    作者:Béla Szőcs、Éva Bokor、Katalin E. Szabó、Attila Kiss-Szikszai、Marietta Tóth、László Somsák
    DOI:10.1039/c5ra05702g
    日期:——
    Bromination of the so obtained compounds by NBS gave hydrazonoyl bromide type derivatives which were ring closed to 3-C-glycosyl-5-substituted-1,2,4-triazoles in pyridine or by NH4OAc in AcOH. Under the same conditions O-perbenzoylated N1-arylidene-C-(β-D-glucopyranosyl)-formamidrazones gave the expected 1,2,4-triazoles as minor products only. N1-Arylidene-arenecarboxamidrazones were also transformed
    在具有多种生物活性的1,2,4-三唑衍生物中,3 - C-吡喃葡萄糖基-5-取代的1,2,4-三唑属于糖原磷酸化酶的最有效抑制剂,因此是潜在的降糖药。在寻找用于这类化合物的新的合成方法中,研究了N 1-亚烷基羧酰胺dra的氧化性闭环。在NaH 2 PO 2存在下,通过Raney-Ni®还原反应,由相应的糖基氰化物和酰氨基prepared酰胺制备O-酰化的N 1-(β- D-甘氨酸金烷基糖基亚甲基)-芳族羧酰胺基酮。通过NBS对如此获得的化合物进行溴化得到了酰肼基溴化物型衍生物,其在吡啶中或在AcOH中通过NH 4 OAc与3- C-糖基-5-取代-1,2,4-三唑闭环。在相同条件下ø -perbenzoylated Ñ 1 -arylidene- Ç - (β- d吡喃葡萄糖基)-formamidrazones给出预期的-1,2,4-三唑作为只有轻微的产品。N 1-亚芳基-亚芳基甲酰胺还与NBS
  • Structure and excitation-dependent emission of novel zinc complexes with pyridyltriazoles
    作者:Alexey Gusev、Elena Braga、Ekaterina Zamnius、Mikhail Kiskin、Mariya Kryukova、Alina Baryshnikova、Boris Minaev、Gleb Baryshnikov、Hans Ågren、Wolfgang Linert
    DOI:10.1039/c9ra02491c
    日期:——

    A series of Zn(ii) complexes with 5-(4-R-phenyl)-3-(pyridin-2-yl)-1,2,4-triazoles have been synthesized and subsequently characterized by single crystal X-ray diffraction, 1H-NMR, FT-IR spectroscopy, elemental analyses, ESI-MS, and PXRD.

    一系列含有5-(4-R-苯基)-3-(吡啶-2-基)-1,2,4-三唑的Zn(ii)配合物已被合成,并随后通过单晶X射线衍射、1H-NMR、FT-IR光谱、元素分析、ESI-MS和PXRD进行表征。
  • Syntheses, characterization and molecular structures of novel Ru(ii), Rh(iii) and Ir(iii) complexes and their possible roles as antitumour and cytotoxic agents
    作者:Gajendra Gupta、Gunjan Sharma、Biplob Koch、Sunhong Park、Shim Sung Lee、Jinkwon Kim
    DOI:10.1039/c3nj00315a
    日期:——
    A series of organometallic arene platinum group metal complexes of the type [(η6-arene)Ru(L)Cl]PF6 arene = benzene; p-cymene and hexamethylbenzene, L = N, N′ ligands} and [(η5-Cp*)M(L)Cl]PF6 (where M = Rh(III) and Ir(III), L = N, N′ ligands) were synthesized. All complexes were isolated as hexafluoridophosphate salts and characterised by elemental analysis, infrared and NMR spectroscopy. The molecular
    一系列所述类型的有机金属芳烃铂族金属配合物[(η 6 -arene)的Ru(L)CL] PF 6 芳烃=苯; p -cymene和六甲,L = Ñ,Ñ '配体}和[(η 5 -Cp *)M(L)CL] PF 6(其中M =铑(III)和Ir(III),L = Ñ,Ñ合成'。所有配合物均被分离为六氟磷酸盐,并通过元素分析,红外和NMR光谱进行表征。的三种具有代表性的复合物中的分子结构1,4和9通过单晶X射线晶体学确定。他们有一个η“琴凳”几何5和η 6协调芳烃配体。合成的络合物的台盼蓝排除和DNA片段化测定显示复合物的有效的抗癌性质5,6和9。化合物6显示最高的抗肿瘤活性,T / C值为211%。
  • Shape-Asymmetry Supramolecular Isomerism in Asymmetrical Ligand PCPs and the Expression Method of Three-Level Isomerism
    作者:Xiaonan Gao、Ai-Yun Fu、Yao-Yu Wang
    DOI:10.1021/acs.inorgchem.6b00081
    日期:2016.5.2
    the primary isomer of 1/2/3 due to the difference of dimensionality. Complex 3 possessing different shape-asymmetry of single networks from 1 and 2, is called as the secondary isomer of 1 and 2. Complexes 1 and 2 possess the same topology, single shape-asymmetry networks, but different interpenetration-orientation and interpenetration-asymmetry, and are defined as the tertiary isomers. Distinct differences
    我们在这里显示了超分子异构体,关于配体的形状不对称和超分子异构体的新层次分类,即三级异构体,它是基于对四个新的Ni / dpt24多晶型物的全面研究而提出的[Hdpt24 = 3 -(2-吡啶基)-5-(4-吡啶基)-1,2,4-三唑)]。化合物1,2,和3是三维互穿双重用的NbO拓扑多孔配位聚合物,而4与二维网格结构被称为初级异构体1 / 2 / 3由于维数的差。复杂3从具有单个网络的不同形状不对称1和2,被称为的次级异构体1和2。配合物1和2具有相同的拓扑结构,单一的形状不对称网络,但是互穿方向和互穿不​​对称性不同,被定义为三级异构体。在每个水平的异构体之间,观察到H 2和CO 2吸附能力的明显差异。另外,还讨论了层次分类与特征分类的关系。
  • A Convenient Strategy for Designing a Soft Nanospace: An Atomic Exchange in a Ligand with Isostructural Frameworks
    作者:Yunsheng Ma、Ryotaro Matsuda、Hiroshi Sato、Yuh Hijikata、Liangchun Li、Shinpei Kusaka、Mawlin Foo、Fengfeng Xue、George Akiyama、Rongxin Yuan、Susumu Kitagawa
    DOI:10.1021/jacs.5b09666
    日期:2015.12.23
    molecules confined in the nanospace of porous materials by single-crystal X-ray diffraction (SXRD) technique is significant because it leads to deep insight into the adsorption mechanism and the actual state of the adsorbents in molecular level. A recent study revealed that flexibility is one of the important factors to achieve periodic guest accommodation in the nanospace enabling direct observation
    通过单晶X射线衍射(SXRD)技术直接观察多孔材料纳米空间中的气体分子具有重要意义,因为它可以在分子水平上深入了解吸附机制和吸附剂的实际状态。最近的一项研究表明,灵活性是在纳米空间中实现周期性客体住宿的重要因素之一,可以直接观察气体分子。在这里,我们报告了一种仅通过配体中的原子交换来调整框架灵活性的便捷策略,这使我们能够轻松构建软纳米空间作为研究气体吸附的最佳平台。事实上,我们成功地使用 SXRD 测量观察到限制在不同配置的柔性多孔配位聚合物 (PCP-N) 孔中的 C2H2 和 CO2 分子,而在晶体学上没有看到与 PCP-N 同构的刚性骨架 (PCP-C) 中的气体分子。PCP-N 的原位粉末 X 射线衍射和吸附测量一致的结果明确表明,骨架可以灵活地转化为以相称的方式捕获气体分子。此外,对于PCP-N,我们发现吸附的气体分子引起显着的结构变化,包括孔隙从一维到三维的尺寸变化,随后,额外
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-